{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:45:14Z","timestamp":1791924314751,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Spanish Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejca.2025.115591","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T02:46:14Z","timestamp":1750733174000},"page":"115591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-2460","authenticated-orcid":false,"given":"Luis P.","family":"del Carpio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2129-6336","authenticated-orcid":false,"given":"Mar","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6953-1490","authenticated-orcid":false,"given":"Mikel","family":"Portu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Villatoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Purqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Gom\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-7257","authenticated-orcid":false,"given":"Daniel","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Llad\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Caminal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3606-1724","authenticated-orcid":false,"given":"Josep M.","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115591_bib1","doi-asserted-by":"crossref","unstructured":"Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma. Arch Ophthalmol.123(12):1639. 2005. doi:10.1001\/archopht.123.12.1639.","DOI":"10.1001\/archopht.123.12.1639"},{"issue":"7","key":"10.1016\/j.ejca.2025.115591_bib2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","article-title":"The genetic evolution of metastatic uveal melanoma","volume":"51","author":"Shain","year":"2019","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejca.2025.115591_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02428-w","article-title":"Punctuated evolution of canonical genomic aberrations in uveal melanoma","volume":"9","author":"Field","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ejca.2025.115591_bib4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ejca.2025.115591_bib5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ophtha.2019.04.027","article-title":"Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D","volume":"126","author":"Vichitvejpaisal","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ejca.2025.115591_bib6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ejca.2025.115591_bib7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115591_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115591_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-46906-4","article-title":"Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility","volume":"15","author":"Leonard-Murali","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejca.2025.115591_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase ii trial by the spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115591_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.ejca.2025.115591_bib12","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.molcel.2024.07.019","article-title":"Molecular impact of mutations in RNA splicing factors in cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Mol Cell"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115591_bib13","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1200\/JCO.2021.39.15_suppl.9535","article-title":"Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)","volume":"39","author":"Grimes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115591_bib14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1038\/s41467-024-46906-4","article-title":"Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility","volume":"15","author":"Leonard-Murali","year":"2024","journal-title":"Nat Commun"},{"issue":"16_","key":"10.1016\/j.ejca.2025.115591_bib15","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1200\/JCO.2023.41.16_suppl.9590","article-title":"Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma","volume":"41","author":"Caplan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115591_bib16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/2159-8290.CD-20-0555","article-title":"Splicing patterns in sf3b1mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes","volume":"11","author":"Bigot","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115591_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-023-01460-5","article-title":"SF3B1 Hotspot Mutations Confer Sensitivity to PARP Inhibition by Eliciting a Defective Replication Stress Response","volume":"55","author":"Bland","year":"2023","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.ejca.2025.115591_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2261278","article-title":"Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients","volume":"12","author":"Garc\u00eda-Mulero","year":"2023","journal-title":"Oncoimmunology"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2026.117056","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:00:00Z","timestamp":1794873600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:50:58Z","timestamp":1791921058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["S0959804925003739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115591","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115591"}}